Just don't get it. Why is a 2-week lag between cases and hospitalizations so hard for some people (MDs no less) to understand? We've only been studying that every day for the last 15 months.
To be specific: Israel wave lagging UK wave by ~2 weeks. Too early for champagne.
The original image (chart labels were cropped away in the above screenshots). I mean I've got the bubbly chilling like everyone else, but I don't see anything to celebrate here.
Yeah, cases triple May 24 to June 14. Hospitalizations triple June 7 to June 28. "It's different this time."
Sure, the non-vaccinated may be younger and healthier, but there will be hospitalizations and not everyone is going to regain their former levels of function.
Israel reached a minimum in case #'s about 14d ago. We can expect hospitalizations to start going up but very very slowly because cases are just now reaching ~100s per day. Expect about 1% hospitalization rate (half young unvaxxed, half older vaxxed)
By contrast, UK was at a minimum in cases 6 weeks ago, and then saw tens of thousands of cases. So we've had 4 weeks to observe the resulting hundreds of new hospitalizations, which are clearly seen above. Perhaps lower hospitalization rate than before, but it's not nothing.
Yet today we get this article: "Delta is not driving a hospitalization surge in England." What did we just see above? The writer may not consider 100s of hospitalizations as a surge, but it's irresponsible and wrong to imply that Delta is not a threat nytimes.com/2021/07/01/hea…
Actually if you look closely at the UK curves, an increase in daily cases by 5000 led to an increase in hospital admissions by 500. So that's a full 10% of cases, which is just as bad as ever. I wonder if there is severe undercounting of cases going on.
Correction about Israel: I'd expect 3% hospitalization rate (derived from 1% in the young unvaxxed and 5% in the old vaxxed, and assuming 50/50 split of cases between them, very roughly speaking). Should not try to post when sleepy. So expect just a few hospitalizations next week
Follow-up to this old thread: I analyzed the UK data as of 7/7 in a separate thread. Sure enough there are hospitalizations, at a lower per-case rate than before, but not that much lower (2.5–3.3% of cases vs 7% in January)
And now the follow-up about Israel. Sadly, but not surprisingly, the Topol-Gandhi celebration (see thread start) was indeed premature.
Weekly hospital admissions have risen by to 67 since 6/20. Rise starts somewhere between 6/20 and 6/27
We see cases start rising on 6/15. That's entirely consistent with hospitalizations rising between 6/20 and 6/27 (lag depends on if cases recorded as infection date or diagnosed date).
Actually if you look at hospitalization trends, Israel was on its way to 0 admissions this week until Delta ruined the party. That means this week's 67 new admissions are basically all from the recent Delta wave (there are ~0 patients being admitted with pre-Delta infections)
So then we can see how many cases gave rise to these 67 admissions. Because the dips lag by 5 days, we'll sum up cases from the week ending 5 days before the last weekly admission number (7/4), which is 6/24 to 6/30. That number is 1552. So hospitalization rate is 67/1552 = 4.3%
I had predicted 3% which was just a wild guess. In the Jan 2021 peak, there were 2000 hospital admissions in 1 week vs 58000 cases, or 3.4%. So the recent 4.3% rate is not lower than pre-Delta.
The 4.3% rate is not different enough from 3.4% to really analyze, but if you wanted to, you could wonder if it's because Delta is more severe (Scotland said you're 2x more likely to land in the hospital) or if people more likely to have severe disease are being diagnosed better.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
FDA has granted regular approval to the Novavax vaccine. What does this mean? A lot of things, all good.
1- It proves Novavax has met efficacy and safety criteria to merit approval outside of the emergency use situation.
Novavax is safer than the RNA vaccines, but ironically the RNA vaccines received full approval earlier than Novavax. That meant Novavax was the only COVID vaccine which vaccine skeptics could incorrectly claim was not safe enough to receive regular approval.
2- Novavax will get to participate in annual booster updates on the same terms as the RNA vaccines. This year's advisory committee for booster strain selection has already been scheduled.
"Novavax had 1.7 systemic symptoms compared with 2.8 in Pfizer recipients. In total, 43.8% of Pfizer vaccinees reported at least one symptom of moderate or higher grade, compared with 24.2% of Novavax"
@RobertKennedyJr in case you didn't know. It's also more broadly protective.
This is the 2nd controlled study to show about half the side effects rate for Novavax vs Pfizer.
Of the 3 covid vaccines, Novavax is the only one still on EUA. Happens it's the smallest of the 3 companies and hasn't hired ex-FDA staffers.
FDA had a deadline of April 2 (this month) to decide on regular approval for Novavax, and reportedly was going to, except Peter Marks resigned the day before. Sadly he didn't sign the approval before he left. Was different for Pfizer and Moderna, who got early review and approval
Our NIH grant to discover coronavirus antiviral meds was terminated today.
With this grant, we had developed a better SARSCoV2 inhibitor than Paxlovid, and we recently discovered an improved drug that looks better than Pfizer's own second-generation inhibitor.
This is part of a complete elimination of COVID19-related research, including on long COVID.
The rationale given is that the pandemic is over.
In reality, people are dying of COVID at several times the rate of flu, and still getting long COVID.
This goes against RFK Jr's stated intention to concentrate on chronic disease.
Long COVID is a bad chronic disease to get, and there are reports of long COVID cases getting better immediately after treatment by protease inhibitors such as the ones we are improving.
I wish sane writers like David Wallace-Wells (and real scientists) had more influence instead of those with an axe to grind or a conflict of interest to protect. Even within @nytimes, he was given a second-fiddle seat. But he keeps his facts, and perspective, straight.
Novavax beats Moderna, which (transiently) induces higher levels of neutralizing Abs. As I've said before, Abs are much more than neutralization. Ab effector functions do most of the clearing, and Novavax seems particularly good at that.
And this is in the 2-dose Phase 3 trials, before the 3rd "booster" dose that, in RNA vaccines but not Novavax, induces antibody (immunoglobulin) class-switching to the no-effector-function IgG4
I made this graphic to show how different vaccine types work (back in 2021).
We can just look at line 1 (protein vax like Novavax) and line 3 (RNA vax).
In protein vax, antigen-presenting cells take up the antigen to activate B cells and Thelper cells....
In RNA vax, your muscles cells take up RNA and translate it into antigen. This process tends to be a bit inflammatory (apparently that's inherent to RNA uptake) so some cells die and release proteins that are also taken up by antigen-presenting cells.